Description
Achora 25 mg tablet contains Tetrabenazine, a prescription medication used to control involuntary,
jerky movements (chorea) Achora 25 mg tablet PRICE IN PAKISTAN associated with Huntington’s disease,
as well as tardive dyskinesia and Achora 25 mg tablet ONLINE Tourette syndrome.
It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor, decreasing Achora 25 mg dopamine to manage motor symptoms.
Tetrabenazine is an inhibitor of the vesicular mono amine transporter 2 (VMAT2). It acts by inhibiting the storage and uptake of certain neurotransmitters in the brain, including dopamine and serotonin, thus normalising their levels and regulating motor activity.
Appearance: Usually circular, yellow-coloured tablets, marked or scored.Major Ingredient: Contains 25 mg of tetrabenazine per single tablet.Minor Ingredients: May include lactose anhydrous, colloidal silicon dioxide, magnesium stearate, and ferric oxide yellow.
Chorea associated with Huntington’s disease.Other therapeutic uses for hyper kinetic disorders like tardive duskiness and Tourette syndrome.
Initial Dosage: Strictly personalised regimen, with a typical starting dose between 12.5 mg to 25 mg per day, which will be incrementally adjusted to achieve maximum benefit with minimum side effects.
Can be consumed either before or during a meal, yet congestion with meals could minimise adverse reactions on the digestive system.Instructions: Should be swallowed intact and never chewed, broken, or divided without scoring.
Psychological Complications: Triggers and aggravates depression, anxiety, and suicidal tendencies.Common Adverse Reactions: Excessive sleepiness, weariness, nausea, and agitation.Drug Interactions: Prohibited with MAOI inhibitors and reserpine.
Close observation needed when combined with other neuroleptics and dopamine antagonists
